Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Lyme Disease Vaccine Candidate Just Misses Its Mark in Late-Stage Trial

(MedPage Today) -- WASHINGTON -- An investigational Lyme disease vaccine covering six serotypes across four Borrelia species had a vaccine efficacy (VE) rate of over 70%, but it just missed a preset noninferiority threshold, a placebo-controlled...

Lyme Disease Vaccine Candidate Just Misses Its Mark in Late-Stage Trial

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Tuesday 27 October →